Effects of kiwi consumption on plasma lipids, fibrinogen and insulin resistance in the context of a normal diet (original) (raw)

Abstract

Background and aims: Among fruits, kiwi is one of the richest in vitamins and polyphenols and has strong anti-oxidant effects. We aimed to analyze the relationship between the consumption of kiwi and plasma lipid values, fibrinogen, and insulin resistance in adults within the context of a normal diet and physical-activity. Methods: Cross-sectional study. Participants (N = 1469), who were free of cardiovascular diseases, completed a visit, which included the collection of information concerning the participant's usual diet and kiwi consumption using a previously validated, semi-quantitative, 137-item food-frequency-questionnaire. Fasting laboratory determinations included plasma lipids, fibrinogen and insulin resistance. Regular physical-activity was determined using accelerometry. Results: Consumers of at least 1 kiwi/week presented higher plasma values of HDL-cholesterol (mean difference 4.50 [95 % CI: 2.63 to 6.36]) and lower triglyceride values (mean difference −20.03 [95 % CI: −6.77 to −33.29]), fibrinogen values (mean difference −13.22 [95 % CI: −2.18 to −24.26]) and HOMAir values (mean difference −0.30 [95 % CI: −0.09 to −0.50]) (p < 0.05, for all comparisons) than those who consumed less than 1 kiwi per week. In an adjusted logistic regression analysis, this group had a lower odds-ratio for presenting plasmatic fibrinogen concentrations above 400 mg/dL (OR = 0.68, 95 % CI 0.49 to 0.95), HDL-Cholesterol plasma values below 45 mg/dL (OR = 0.57, 95 % CI 0.36 to 0.91) and a HOMAir above 3 (OR = 0.61, 95 % CI 0.37 to 1.00). Conclusions: Consumption of at least one kiwi/week is associated with lower plasma concentrations of fibrinogen and improved plasma lipid profile in the context of a normal diet and regular exercise.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (43)

  1. Coordinating center (Primary Care Research Unit, La Alamedilla Health Center, Salamanca, Spain): L. Garcia Ortiz, MA Gómez Marcos, JI Recio Rodriguez, and MC Patino Alonso. Participating centers: La Alamedilla Health Center (Health Service of Castilla y León): MC Castaño Sánchez, C. Rodríguez Martín, Y. Castaño Sánchez, C. Agudo Conde, E. Rodríguez Sánchez, LJ González Elena, C. Herrero Rodríguez, B. Sánchez Salgado, A. de Cabo Laso, JA Maderuelo Fernández. Passeig de Sant Joan Health Center (Catalan Health Service): C. Martín Cantera, J. Canales Reina, E. Rodrigo de Pablo, M L. Lasaosa Medina, MJ. Calvo Aponte, A. Rodríguez Franco, E. Briones Carrio, C. Martin Borras, A. Puig Ribera, R. Colominas Garrido. Poble Sec Health Center (Catalán Health Service): J. Anton Alvarez, MªT. Vidal Sarmiento, Á.
  2. Viaplana Serra, S. Bermúdez Chillida, A. Tanasa. Ca N'Oriac Health Center (Catalan Health Service): M. Romaguera Bosch. Sant Roc Health Center (Catalán Health Service): MM. Domingo, A. Girona, N. Curos, FJ Mezquiriz, L. Torrent. Cuenca III Health Center (Health Service of Castilla-La Mancha): A.Cabrejas Sánchez, MT Pérez Rodríguez, ML. García, JL. Bartolomé, F. Salcedo Aguilar. Casa del Barco Health Center (Health Service of Castilla y León): C. Fernández Alonso, A. Gómez Arranz, E. Ibáñez Jalón, A. de la Cal de la Fuente, N. Gutiérrez, L. Muñoz, M. Menéndez, I. Repiso, R. Sanz Cantalapiedra, LM. Quintero González, S. de Francisco Velasco, MA.
  3. Diez García, E. Sierra Quintana, M.Cáceres. Torre Ramona Health Center (Health Service of Aragon): N. González Viejo, JF. Magdalena Belio, L. Otegui Ilarduya, FJa.
  4. Rubio Galán, A. Melguizo Bejar, CI. Sauras Yera, MªJ. Gil Train, M. Iribarne Ferrer, MA. Lafuente Ripolles. Primary Care Research Unit of Bizkaia (Basque Health Service-Osakidetza): G. Grandes, A. Sanchez, N. Guenaga, V. Arce, MS.
  5. Arietaleanizbeaskoa, E.Iturregui San Nicolás, RA. Martín Santidrián, A Zuazagoitia. References
  6. Hartley L, Igbinedion E, Holmes J, Flowers N, Thorogood M, Clarke A, et al. Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev. 2013;6:CD009874.
  7. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342(8878):1007-11.
  8. Macready AL, George TW, Chong MF, Alimbetov DS, Jin Y, Vidal A, et al. Flavonoid-rich fruit and vegetables improve microvascular reactivity and inflammatory status in men at risk of cardiovascular disease-FLAVURS: a randomized controlled trial. Am J Clin Nutr. 2014;99(3):479-89.
  9. Toh JY, Tan VM, Lim PC, Lim ST, Chong MF. Flavonoids from fruit and vegetables: a focus on cardiovascular risk factors. Curr Atheroscler Rep. 2013;15(12):368.
  10. Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships. Agents Actions. 1982;12(3):382-7.
  11. Iwasawa H, Morita E, Yui S, Yamazaki M. Anti-oxidant effects of kiwi fruit in vitro and in vivo. Biol Pharm Bull. 2011;34(1):128-34.
  12. Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, et al. A systematic screening of total antioxidants in dietary plants. J Nutr. 2002;132(3):461-71.
  13. Pellegrini N, Serafini M, Colombi B, Del Rio D, Salvatore S, Bianchi M, et al. Total antioxidant capacity of plant foods, beverages and oils consumed in Italy assessed by three different in vitro assays. J Nutr. 2003;133(9):2812-9.
  14. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992;18(1):1-29.
  15. Motohashi N, Shirataki Y, Kawase M, Tani S, Sakagami H, Satoh K, et al. Cancer prevention and therapy with kiwifruit in Chinese folklore medicine: a study of kiwifruit extracts. J Ethnopharmacol. 2002;81(3):357-64.
  16. Collins BH, Horska A, Hotten PM, Riddoch C, Collins AR. Kiwifruit protects against oxidative DNA damage in human cells and in vitro. Nutr Cancer. 2001;39(1):148-53.
  17. Edmunds SJ, Roy NC, Love DR, Laing WA. Kiwifruit extracts inhibit cytokine production by lipopolysaccharide-activated macrophages, and intestinal epithelial cells isolated from IL10 gene deficient mice. Cell Immunol. 2011;270(1):70-9.
  18. Lee DE, Shin BJ, Hur HJ, Kim JH, Kim J, Kang NJ, et al. Quercetin, the active phenolic component in kiwifruit, prevents hydrogen peroxide-induced inhibition of gap-junction intercellular communication. Br J Nutr. 2010;104(2):164-70.
  19. Jung KA, Song TC, Han D, Kim IH, Kim YE, Lee CH. Cardiovascular protective properties of kiwifruit extracts in vitro. Biol Pharm Bull. 2005;28(9):1782-5.
  20. Gammon CS, Kruger R, Conlon CA, von Hurst PR, Jones B, Stonehouse W. Inflammatory status modulates plasma lipid and inflammatory marker responses to kiwifruit consumption in hypercholesterolaemic men. Nutr Metab Cardiovasc Dis. 2014;24(1):91-9.
  21. Duttaroy AK, Jorgensen A. Effects of kiwi fruit consumption on platelet aggregation and plasma lipids in healthy human volunteers. Platelets. 2004;15(5):287-92.
  22. Abe D, Saito T, Kubo Y, Nakamura Y, Sekiya K. A fraction of unripe kiwi fruit extract regulates adipocyte differentiation and function in 3 T3-L1 cells. Biofactors. 2010;36(1):52-9.
  23. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311(8):501-5.
  24. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10.
  25. Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013;12:159.
  26. Hellgren MI, Daka B, Jansson PA, Lindblad U, Larsson CA. Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity. Eur J Prev Cardiol. 2015;22(7):940-9.
  27. Garcia-Ortiz L, Recio-Rodriguez JI, Schmidt-Trucksass A, Puigdomenech-Puig E, Martinez-Vizcaino V, Fernandez-Alonso C, et al. Relationship between objectively measured physical activity and cardiovascular aging in the general population-the EVIDENT trial. Atherosclerosis. 2014;233(2):434-40.
  28. Patino-Alonso MC, Recio-Rodriguez JI, Belio JF, Colominas-Garrido R, Lema-Bartolome J, Arranz AG, et al. Factors associated with adherence to the Mediterranean diet in the adult population. J Acad Nutr Diet. 2014;114(4):583-9.
  29. Garcia-Ortiz L, Recio-Rodriguez JI, Martin-Cantera C, Cabrejas-Sanchez A, Gomez-Arranz A, Gonzalez-Viejo N, et al. Physical exercise, fitness and dietary pattern and their relationship with circadian blood pressure pattern, augmentation index and endothelial dysfunction biological markers: EVIDENT study protocol. BMC Public Health. 2010;10:233.
  30. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101-23.
  31. Bergstrom K, Lefvert AK. An automated turbidimetric immunoassay for plasma proteins. Scand J Clin Lab Invest. 1980;40(7):637-40.
  32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
  33. Fernandez-Ballart JD, Pinol JL, Zazpe I, Corella D, Carrasco P, Toledo E, et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr. 2010;103(12):1808-16.
  34. Melanson Jr EL, Freedson PS. Validity of the Computer Science and Applications, Inc. (CSA) activity monitor. Med Sci Sports Exerc. 1995;27(6):934-40.
  35. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. Med Sci Sports Exerc. 1998;30(5):777-81.
  36. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1-78.
  37. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 2003;96(10):711-29.
  38. Schneider DJ, Taatjes DJ, Howard DB, Sobel BE. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol. 1999;33(1):261-6.
  39. Chang WH, Liu JF. Effects of kiwifruit consumption on serum lipid profiles and antioxidative status in hyperlipidemic subjects. Int J Food Sci Nutr. 2009;60(8):709-16.
  40. Gammon CS, Kruger R, Minihane AM, Conlon CA, von Hurst PR, Stonehouse W. Kiwifruit consumption favourably affects plasma lipids in a randomised controlled trial in hypercholesterolaemic men. Br J Nutr. 2013;109(12):2208-18.
  41. Wang B, Liu K, Mi M, Wang J. Effect of fruit juice on glucose control and insulin sensitivity in adults: a meta-analysis of 12 randomized controlled trials. PLoS One. 2014;9(e95323).
  42. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. [Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population].
  43. Med Clin (Barc). 2001;117(14):530-3.